# psoriasis - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 6
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 66494
- Completion tokens: 43059
- Reasoning tokens: 11613
- Total tokens: 109553
- API requests reported: 5
- Elapsed seconds: 148.342
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 4/5; original repeat 6; model vendor: MiniMax

---
<think>The user is asking for a comprehensive biological interpretation of transcriptomic data from psoriatic lesional skin vs. normal control skin. Let me carefully analyze the data:

**Data summary:**
- 100 genes total: 90 upregulated, 10 downregulated
- All FDR ≤ 0.01 (highly significant)
- All P values ≤ 0.05
- Effect sizes (log2FC) range from -6.25 (LOC107984452) to +11.37 (IL36A)

**Major upregulated genes by theme:**
1. **IL-36/IL-1 family cytokines**: IL36A (11.37), IL36G (5.68), IL36RN (3.00), IL19 (7.58), IL20 (5.67), IL26 (4.36)
2. **Antimicrobial peptides**: DEFB4A (11.18), DEFB4B (11.03), DEFB103A (5.76), DEFB103B (5.75), PI3 (9.24), S100A7 (7.10), S100A7A (9.83), S100A8 (7.73), S100A12 (8.33)
3. **Keratinization/cornified envelope**: SPRR2A/B/D/E/F/G, LCE3A (8.30), LCE3D (5.31), KRT6A (4.30), SPRR3 (7.18)
4. **Serine protease inhibitors (SERPINs)**: SERPINB3 (6.74), SERPINB4 (9.12), SERPINB13 (3.09), SERPINB11 (4.47)
5. **Chemokines/receptors**: CXCL13 (5.89), CXCR2 (2.70), GPR15LG (5.52), CD274/PD-L1 (3.44)
6. **Keratinocyte differentiation regulators**: WNT5A (2.53), FABP5 (3.64), KYNU (4.42), AKR1B10 (6.27), AKR1B15 (5.23)
7. **Cell proliferation**: CCNE1 (2.56), RRM2 (2.72), CDK5R1 (2.35)
8. **Gap junctions**: GJB2 (4.42), GJB6 (3.02)
9. **NF-κB negative regulators**: TNIP3 (7.28), ZC3H12A (3.85)
10. **Kinases/signaling**: PRKCQ (2.88), IRAK2 (2.08), HRH2 (3.27), PLA2G4D (4.62), PLA2G4E (2.47)

**Downregulated genes:**
- LOC107984452 (-6.25)
- BTC (Betacellulin, -4.30)
- LOC105371988 (-4.10)
- CYP2W1 (-4.70)
- LINC02660 (-3.90)
- LOC107984005 (-4.27)
- SAPCD1 (-2.94)
- UGT3A2 (-4.59)
- WAKMAR1 (-5.63)
- SAPCD1-AS1 (-2.84)

**Pathway/ontology enrichment from RAG:**
- Response to LPS (GO:0032496)
- Epidermis development (GO:0008544)
- Antimicrobial humoral response (GO:0019730)
- IL-17 signaling pathway (KEGG)
- Cytokine-cytokine receptor interaction (KEGG)
- S. aureus infection (KEGG)
- Formation of cornified envelope (Reactome)

**STRING network evidence:**
- SPRR1B cluster with KRT6A, SPRR2A/B/D/E
- S100A7 cluster with FABP5, S100A12, S100A7A, SERPINB3/B4
- CCR6 cluster with DEFB103A, DEFB4A/B
- CTSG cluster with SERPINB13, SERPINB3, SERPINB4
- IL1RAP cluster with IL36A, IL36G, IL36RN
- GNAS cluster with HRH2, PLA2G4D/E

**Independent cohort validation:** NOT AVAILABLE - this is critical to note.

Now I'll structure the answer:

1. **Overall biological interpretation**: This is a classic psoriasis transcriptomic signature dominated by:
   - Keratinocyte hyperproliferation/differentiation (cornified envelope)
   - Antimicrobial defense (β-defensins, S100 alarmins)
   - IL-17/IL-22/IL-36 inflammatory cytokine axis
   - Neutrophil chemotaxis
   - Lipid/keratin metabolism (AKR1B10, FABP5, KYNU)

2. **Core programs** (limit 5):
   - IL-17/IL-36/IL-20 inflammatory cytokine program
   - Antimicrobial peptide/alarmin program
   - Cornified envelope/keratinocyte terminal differentiation program
   - Serine protease/serpin dysregulation
   - Keratinocyte hyperproliferation/cell cycle program

3. **Key genes** (limit 10):
   - IL36A, IL36G, IL36RN
   - DEFB4A/B
   - S100A7/A7A/A8/A12
   - SPRR2 family (multiple)
   - KRT6A
   - SERPINB3/B4
   - CXCL13, CXCR2
   - WNT5A, KYNU, AKR1B10
   - CCNE1, RRM2
   - TNIP3

4. **Validation priorities** (limit 5):
   - IL-36 axis as therapeutic target (supported hypothesis)
   - DEFB4/S100 alarmin panel as biomarker (supported hypothesis)
   - SPRR2/LCE3 cornified envelope program - mechanistic hypothesis
   - Serpin-protease balance (SERPINB/KLK13) - mechanistic
   - Cell composition confound check (neutrophil-driven DEFB4/CXCL13 vs keratinocyte-driven IL-36)

5. **Evidence grounding**: All input = direct evidence. RAG pathway/ontology = contextual. STRING = network. Independent cohort = NOT AVAILABLE.

6. **Limitations**: Cell composition (neutrophils, T cells, keratinocytes), no independent validation, all FDR significant, lncRNAs may be unreliable, batch effects possible, missing clinical covariates.

Let me draft a thorough, evidence-grounded response. I should be careful to:
- Distinguish direct (uploaded) from external/contextual evidence
- Note that no independent cohort validation was performed
- Use program-level synthesis, not per-gene
- Cite specific gene evidence properly
- End with a complete sentence</think>

# Multidimensional interpretation of psoriatic lesional skin vs. normal control transcriptomics

## 1. Overall biological interpretation

The 100-gene signature is overwhelmingly skewed toward activation (90 up, 10 down; all FDR ≤ 0.01), with many of the strongest effect sizes exceeding log2FC ≈ 6–11. The dominant biological themes converge on what is already the canonical molecular picture of psoriasis: (i) hyperproliferative, abnormally differentiated keratinocytes producing a thickened cornified envelope; (ii) a self-amplifying cytokine circuit driven by IL-17/IL-22/IL-36 family members; (iii) a massive antimicrobial/alarmin response dominated by β-defensins and S100 proteins; and (iv) neutrophil and lymphocyte chemotaxis. A secondary keratinocyte-intrinsic metabolic axis (lipid-binding proteins, aldo-keto reductases, tryptophan catabolism via KYNU, non-canonical WNT signaling) is also strongly represented. The few downregulated genes are largely lineage-restricted lncRNAs/loci, a growth-factor (BTC/betacellulin), a cytochrome (CYP2W1), and a glycosyltransferase (UGT3A2) — i.e., loss of homeostatic/barrier-maintenance transcripts rather than a coherent "suppressed" pathway.

**Important caveat:** No independent cohort statistic was supplied (Evidence Adjudication: independent cohort validation = not_available). All "concordance" statements below refer to overlap with established literature/database annotations, not to replication in a second dataset.

---

## 2. Core biological programs (max 5)

### Program A — IL-17 / IL-36 / IL-20 inflammatory cytokine axis
- **Direction:** Upregulated.
- **Supporting genes (uploaded, log2FC):** IL36A (11.37), IL36G (5.68), IL36RN (3.00), IL19 (7.58), IL20 (5.67), IL26 (4.36); reinforced by chemokines CXCL13 (5.89), receptors CXCR2 (2.70), GPR15LG (5.52), and signaling adaptors IRAK2 (2.08) and PRKCQ (2.88).
- **Pathway mapping:** KEGG "IL-17 signaling pathway" and "Cytokine-cytokine receptor interaction"; Reactome "Interleukin-36 pathway" (R-HSA-9014826), "Interleukin-20 family signaling" (R-HSA-8854691).
- **Why this is a program:** Multiple ligands of the IL-1/IL-36 and IL-20 families are co-elevated together with receptors and downstream JAK-STAT/MAPK signaling components — exactly the keratinocyte–T-cell feed-forward loop thought to sustain psoriatic plaques.
- **Evidence strength:** Strong within-cohort (consistent direction, very large effect sizes, FDR < 1e-60 for IL36A). STRING shows a direct physical interaction module IL1RAP–IL36A/IL36G/IL36RN and IL26–IL10RB/IL20RA/IL19 (high STRING confidence, 0.90–0.999).
- **Limitations:** Direct causal evidence (functional knockdown) is not present in the uploaded table; literature support is contextual only, not a new statistic.

### Program B — Antimicrobial peptide and alarmin program (innate antimicrobial shield)
- **Direction:** Upregulated.
- **Supporting genes:** DEFB4A (11.18), DEFB4B (11.03), DEFB103A (5.76), DEFB103B (5.75), PI3 (9.24), S100A7 (7.10), S100A7A (9.83), S100A8 (7.73), S100A12 (8.33), LCN-type marker TCN1 (8.04), GDA (5.90), and the protease HPSE (2.92).
- **Pathway mapping:** GO "Antimicrobial humoral response" (GO:0019730); Reactome "Defensins"; KEGG "Staphylococcus aureus infection" (KEGG capture reflects the cathelicidin/β-defensin antimicrobial module, not literal infection).
- **Why this is a program:** DEFB4A/B are the prototypical IL-17A/IL-22 target genes in keratinocytes; their extreme effect sizes here, paired with S100A7/A8/A12 (classical alarmins) and additional β-defensins, mark this as the "keratinocyte antimicrobial burst" program.
- **Evidence strength:** Strong within-cohort; STRING cluster CCR6–DEFB103A/DEFB4A/DEFB4B indicates co-expression rather than direct physical binding.
- **Limitations:** β-defensin signal is strongly neutrophil- and keratinocyte-driven; without cell-type deconvolution it cannot be cleanly attributed to one source (see §6).

### Program C — Cornified envelope and epidermal terminal differentiation
- **Direction:** Upregulated.
- **Supporting genes:** SPRR2A/B/D/E/F/G (log2FC 3.99–7.31), LCE3A (8.30), LCE3D (5.31), KRT6A (4.30), SPRR3 (7.18), SERPINB3 (6.74), SERPINB4 (9.12), SERPINB13 (3.09), SERPINB11 (4.47), FABP5 (3.64), GJB2 (4.42), GJB6 (3.02).
- **Pathway mapping:** GO "Epidermis development" (GO:0008544); Reactome "Formation of the cornified envelope" (R-HSA-6809371; 12 of the 100 genes overlap including KLK13, KRT6A, LCE3A, LCE3D, PI3).
- **Why this is a program:** Late-cornified envelope (LCE3) and small proline-rich (SPRR2) families, together with hyperproliferation-associated keratin KRT6A and SERPINB serine protease inhibitors, reflect the abnormal terminal-differentiation program that produces the parakeratotic, thickened stratum corneum of psoriatic plaques.
- **Evidence strength:** Strong within-cohort; STRING network shows SPRR1B-centered co-expression of KRT6A and SPRR2A/B/D/E, indicating pathway co-membership, not direct physical binding.
- **Limitations:** Some of these genes (e.g., SERPINB3/4) also overlap with Program E (protease/serpin dysregulation).

### Program D — Keratinocyte metabolic / lipid-handling reprogramming
- **Direction:** Upregulated.
- **Supporting genes:** AKR1B10 (6.27), AKR1B15 (5.23), KYNU (4.42), WNT5A (2.53), FABP5 (3.64), PLA2G4D (4.62), PLA2G4E (2.47), HRH2 (3.27), RHCG (5.29), SLC6A14 (4.47).
- **Pathway mapping:** GO "Response to lipopolysaccharide" (GO:0032496) overlaps partly via PLA2G4D/E; KEGG captures it under broader cytokine/inflammation terms. STRING cluster GNAS–HRH2–PLA2G4D–PLA2G4E reflects pathway co-membership in phospholipid/HRH signaling.
- **Why this is a program:** Aldo-keto reductases (AKR1B10/15) and fatty acid–binding protein FABP5 are classic psoriasis-induced keratinocyte markers; KYNU is the IL-17-induced tryptophan-catabolic enzyme driving aryl-hydrocarbon-receptor ligand generation; WNT5A is the non-canonical WNT ligand characteristic of psoriasis (vs. WNT3A in atopic dermatitis). The directionality here is consistent with published keratinocyte "lipid-aromatic" reprogramming.
- **Evidence strength:** Moderate; effects are large but gene count is smaller than Programs A/B.
- **Limitations:** No direct enzymatic activity assay is provided; the metabolic flux interpretation is hypothesis-grade.

### Program E — Keratinocyte hyperproliferation / cell-cycle drive
- **Direction:** Upregulated.
- **Supporting genes:** CCNE1 (2.56), RRM2 (2.72), CDK5R1 (2.35), TPBG (1.86), plus the proliferation-coupled SERPINB/PI3/alarmins in Programs B/C.
- **Pathway mapping:** Hallmark "E2F targets" / "G2M checkpoint" implied; not a top retrieved module but consistent with known psoriatic keratinocyte biology.
- **Why this is a program:** CCNE1 + RRM2 + TPBG mark cycling keratinocytes; this is a smaller, distinct program supporting the histological acanthosis.
- **Evidence strength:** Directionally consistent in the uploaded table; effect sizes are smaller than Programs A/B/C.
- **Limitations:** Small gene count in the list; risk of being driven by residual cycling basal-layer cells rather than lesional pathology per se.

The 10 downregulated genes do not form a coherent counter-program. LOC107984452 (-6.25), WAKMAR1 (-5.63), CYP2W1 (-4.70), UGT3A2 (-4.59), BTC (-4.30), LOC107984005 (-4.27), LOC105371988 (-4.10), LINC02660 (-3.90), SAPCD1 (-2.94), SAPCD1-AS1 (-2.84) are dominated by uncharacterized loci and lncRNAs, plus BTC (an EGFR ligand normally expressed by keratinocytes) and CYP2W1. The downregulation pattern is consistent with loss of normal homeostatic/barrier transcripts rather than an active anti-psoriatic program; I therefore do not propose a "downregulated program" as a major finding.

---

## 3. Key genes and interaction modules (≤10)

I prioritize by (a) effect size and FDR in the uploaded table, (b) recurrence across multiple RAG sources, and (c) known centrality in psoriasis biology. None of these should be read as "causal" without experimental perturbation.

1. **IL36A (log2FC +11.37, FDR 1.65e-98)** — Top-ranked pro-inflammatory cytokine. STRING: direct high-confidence interaction with IL1RAP and IL36G/IL36RN (pathway co-membership in the IL-36 axis). Represents Program A. Supported hypothesis for therapeutic targeting (anti-IL-36R biologics, e.g., spesolimab, are clinically validated in pustular psoriasis — external literature, not from the uploaded table).

2. **DEFB4A / DEFB4B (log2FC +11.18, +11.03)** — IL-17A target genes; represent Program B. STRING co-expression cluster with DEFB103A/DEFB103B via CCR6 (co-expression, not direct binding). Classic biomarker for IL-17 pathway activity.

3. **S100A7A / S100A7 / S100A8 / S100A12 (log2FC +9.83 to +7.73)** — Alarmins central to Program B. STRING shows a tight S100A7/FABP5/S100A12/S100A7A/SERPINB3/SERPINB4 co-expression module (network co-membership, not direct physical binding). Read-out for IL-17/IL-22-driven keratinocyte alarm signaling.

4. **SPRR2 family (SPRR2A/B/D/E/F/G, log2FC 3.99–7.31) + LCE3A/D + KRT6A** — Program C. STRING evidence shows co-expression (SPRR1B-centered) — pathway co-membership rather than direct binding. Mechanistic hypothesis-grade.

5. **SERPINB3 / SERPINB4 (log2FC +6.74, +9.12)** — Serine protease inhibitors dysregulated in keratinocyte cornification; STRING co-expression with SERPINB13 (via CTSG node) indicates regulatory co-membership rather than direct interaction. Biomarker candidates in psoriasis and some epithelial cancers.

6. **CXCL13 (log2FC +5.89) and CXCR2 (log2FC +2.70)** — Chemokine–receptor pair supporting Program A and neutrophil/T-cell trafficking. Co-membership in cytokine-cytokine receptor interaction pathway (KEGG); not direct binding without further evidence.

7. **WNT5A (log2FC +2.53) + KYNU (log2FC +4.42) + AKR1B10 (log2FC +6.27)** — Triplet representing Program D (non-canonical WNT, tryptophan catabolism, aldo-keto reductase). Each maps to a distinct GO/Reactome term; their co-elevation supports the metabolic-reprogramming hypothesis.

8. **TNIP3 (log2FC +7.28) + ZC3H12A (log2FC +3.85) + IRAK2 (log2FC +2.08)** — NF-κB negative regulators and TLR/IL-1R adaptors. Pathway co-membership in NF-κB signaling; suggests an attempted compensatory brake on inflammation (supported hypothesis, mechanism not established from the table).

9. **CCNE1 (log2FC +2.56) + RRM2 (log2FC +2.72)** — Cell-cycle program (Program E). Pathway co-membership in cell-cycle / DNA replication modules; not direct physical interaction.

10. **PD-L1 / CD274 (log2FC +3.44)** — Immune checkpoint ligand upregulated in lesional keratinocytes; co-membership with T-cell exhaustion markers elsewhere in the disease (literature-supported but not a new independent statistic). Therapeutic-relevance hypothesis.

Interaction-type discipline: every STRING statement above is co-expression / pathway co-membership unless confidence is ≥0.7 *and* interaction type is annotated as "physical binding" (the only true direct physical interactions in this pack are IL26–IL10RB/IL20RA, IL36RN–IL1RL2, and similar high-confidence cytokine–receptor pairs from STRING). All other "hub" statements (SPRR1B, S100A7, CCR6, CTSG, GNAS nodes) are co-expression / network co-membership.

---

## 4. Validation priorities (≤5)

### V1 — IL-36 axis as a therapeutic target (Therapeutic target)
- **Why prioritize:** Largest uploaded effect size (IL36A log2FC +11.37) plus coordinated upregulation of IL36G and IL36RN suggests strong, coherent axis activation.
- **Dataset evidence:** All three IL36-family members upregulated with FDR ≤ 4e-62; STRING shows a physical interaction module IL1RAP–IL36A/G/RN.
- **External evidence:** Anti-IL-36R antibodies (spesolimab, imsidolimab) are clinically validated in generalized pustular psoriasis (external literature, not the uploaded table).
- **Next step:** Stratify the cohort by IL36A expression and test whether IL-36A-high lesions show stronger response to IL-36R blockade (requires independent cohort + trial data).
- **Status:** **Supported hypothesis** (within-cohort direction is consistent and biologically coherent; clinical validation exists externally but is not reproduced here).

### V2 — DEFB4A/B + S100A7/A8/A12 alarmin panel as a lesional biomarker (Biomarker)
- **Why prioritize:** Six of the top-20 upregulated genes are β-defensins or S100 alarmins, all FDR < 1e-65.
- **Dataset evidence:** DEFB4A 11.18, DEFB4B 11.03, S100A7A 9.83, PI3 9.24, SERPINB4 9.12, S100A7 7.10, S100A8 7.73, S100A12 8.33.
- **External evidence:** These are established IL-17 readouts in the literature and are used as endpoints in anti-IL-17 trials (contextual only).
- **Next step:** Quantitative RT-PCR or Luminex assay of DEFB4 + S100A7/A8 in biopsies and tape-strips; correlate with PASI score in an independent cohort.
- **Status:** **Supported hypothesis**.

### V3 — SPRR2 / LCE3 / SERPINB cornified-envelope program (Mechanistic hypothesis)
- **Why prioritize:** Multiple genes from the same pathway are coordinately elevated (SPRR2 family 6 paralogs, LCE3A/D, SERPINB3/B4/B11/B13).
- **Dataset evidence:** Effect sizes 3–9 log2FC; Reactome "Formation of the cornified envelope" contains 12 of the 100 genes.
- **External evidence:** SPRR2 dysregulation is documented in psoriatic epidermis (contextual only).
- **Next step:** Immunohistochemistry of SPRR2A/B and LCE3A in lesional vs. non-lesional biopsies to confirm protein-level changes and cellular localization (suprabasal keratinocytes vs. neutrophils).
- **Status:** **Supported hypothesis** for transcript-level program; mechanistic role in plaque architecture is **exploratory**.

### V4 — Cell-composition / confounding check (Confounding or composition check)
- **Why prioritize:** Several top hits (DEFB4A/B, CXCL13, CXCR2, S100A8/A12) are strongly expressed by neutrophils, which infiltrate psoriatic plaques heavily.
- **Dataset evidence:** Cannot be resolved from the table alone — uploaded values are bulk RNA.
- **External evidence:** Cell-type marker databases (HPA, GTEx) and published scRNA-seq of psoriatic skin both show neutrophil contributions to these genes.
- **Next step:** Re-analyze the data with deconvolution (CIBERSORTx, MuSiC, or single-cell reference) and check whether the program-level conclusions (especially Programs A and B) hold after adjusting for neutrophil/lymphocyte fraction.
- **Status:** **Exploratory hypothesis** (the confounding is plausible and well-documented; the magnitude in this specific dataset is unmeasured).

### V5 — KYNU / AKR1B10 / WNT5A metabolic-reprogramming axis (Mechanistic hypothesis)
- **Why prioritize:** Smaller gene count than Programs A/B/C, but each gene is a strong, well-annotated psoriasis marker and they point to a testable metabolic mechanism.
- **Dataset evidence:** KYNU +4.42, AKR1B10 +6.27, AKR1B15 +5.23, WNT5A +2.53.
- **External evidence:** KYNU is an IL-17-induced enzyme that generates AHR ligands; AKR1B10 is a psoriasis-induced keratinocyte aldose reductase (contextual literature).
- **Next step:** LC-MS measurement of kynurenine pathway metabolites and AHR activity in lesional biopsies; test whether AKR1B10 inhibition (epalrestat is a known aldose reductase inhibitor with reported anti-tumor activity in PMID 39017606) alters keratinocyte IL-17 responses in vitro.
- **Status:** **Exploratory hypothesis**.

---

## 5. Evidence grounding — what each claim rests on

- **Direct evidence from this dataset:** All log2FC, FDR, and direction statements in §2 and §3 are from the uploaded table. Independent-cohort replication was **not available**, so any "replication" or "validated" framing here would be inappropriate; concordance with literature is described as contextual.
- **Pathway / ontology evidence:** Recurrence in GO:0032496, GO:0008544, GO:0019730, KEGG IL-17/cytokine-receptor/Staphylococcus aureus infection, and Reactome cornified-envelope / IL-36 / IL-20 family modules — retrieved, not newly computed.
- **Protein / regulatory network evidence:** STRING edges indicate co-expression / co-membership; high-confidence (≥0.9) cytokine–receptor pairs (e.g., IL26–IL10RB, IL36RN–IL1RL2) represent direct physical interactions. Other "hub" relationships are network co-membership.
- **Disease-association evidence:** GWAS (100/100 selected items returned records), ClinVar (90/100), Open Targets (90/100) — these are prior associations in databases, not new statistics for this cohort.
- **Expression / tissue evidence:** GTEx (83/100) and HPA (76/100) provide tissue-level expression context (used only to gauge plausibility, not to overwrite effect sizes).
- **Drug / therapeutic evidence:** ChEMBL (11/100) and ClinicalTrials.gov (40/100) records exist for some selected genes; their mere existence does **not** validate those genes as effective psoriasis targets.
- **Literature evidence:** PubMed (669 articles) and Europe PMC (848 articles) were retrieved; representative psoriasis-relevant records include PMID 40560938 (psoriasis WGCNA + LASSO biomarkers) and Europe PMC 42216026 (KRT6A in alopecia areata as biomarker). These are contextual, not new statistics.

**Source independence note:** Many "independent" sources (GWAS, Open Targets, ClinVar, Ensembl) draw on overlapping underlying publications and shared gene-to-disease mappings. STRING network co-expression edges are often computed from the same transcriptomic studies that produced the uploaded table. Therefore co-occurrence across these sources is **not** equivalent to independent biological replication.

**Conflicts:** None explicitly identified across sources, but the absence of independent cohort statistics means any "agreement" claim is structurally weak.

---

## 6. Limitations and alternative explanations (≤5)

1. **Cell-composition confounding (key limitation).** Psoriatic plaques contain infiltrating neutrophils, dendritic cells, and T cells that are absent from normal skin. Genes like DEFB4A/B, S100A8/A12, CXCL13, CXCR2, and GPR15LG are strongly neutrophil- or lymphocyte-derived. Without deconvolution or single-cell validation, the "keratinocyte-centric" interpretation is partially confounded. Mitigation: CIBERSORTx or scRNA-seq deconvolution (see V4).

2. **No independent cohort statistic was supplied.** The Evidence Adjudication block explicitly states external cohort validation = not_available. Effect sizes in this single cohort may be cohort-specific (sampling site, severity, treatment exposure). Any claim that a program is "established" in psoriasis must rest on literature, not on the uploaded table.

3. **Treatment exposure is unmeasured.** Biologic-naïve vs. biologic-exposed patients can produce substantially different transcriptomes. If the lesional cohort includes patients on partial treatment, programs may be partially suppressed (especially IL-17/IL-23 axis). Clinical metadata are not provided in the input.

4. **lncRNA / uncharacterized locus entries.** Many of the top up- and downregulated hits are lncRNAs or unannotated loci (LOC105376238, LOC105376239, LOC107984452, LOC107984005, LOC105371569, LOC105371988, LOC105376342, KLHDC7B-DT, LINC01206/01269/01605/01215/03232/02660, WAKMAR1, SAPCD1-AS1). These are statistically robust in this dataset, but their functional interpretation is **insufficient evidence** for any biological role; they should be treated as candidate loci pending functional studies.

5. **Association ≠ causation.** All log2FC values are associations, not perturbation effects. Genes with the largest effect sizes (IL36A, DEFB4A/B, PI3, S100A7A) may be downstream readouts of the IL-17/IL-22/IL-36 driver axis rather than primary drivers. Mechanistic claims require genetic or pharmacologic perturbation in keratinocytes or relevant immune cells.

**In summary,** the data depict the canonical IL-17/IL-36/keratinocyte-differentiation signature of psoriatic lesional skin with strong within-cohort statistical support, but no independent replication is available, the neutrophil contribution is unaccounted for, and the functional role of the most upregulated lncRNAs remains unexplored. The strongest, most actionable priorities are (V1) IL-36 axis blockade, (V2) a DEFB4/S100 alarmin biomarker panel, and (V4) cell-composition deconvolution before any of these programs are interpreted as purely keratinocyte-intrinsic.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=3, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
